Efficacy and Tolerability of Intravenous Ferric Carboxymaltose in Patients with Iron Deficiency at a Hospital Outpatient Clinic: A Retrospective Cohort Study of Real-World Clinical Practice
Table 1
Demographic and clinical characteristics of the study population.
Characteristic
Patients (N = 459)
Age (years), mean (SD)
58.6 (17.5)
Elderly > 65 years, n (%)
187 (40.7)
Male, n (%)
101 (22.0)
Anemia, n (%)
378 (82.4)
Iron deficiency, n (%)
450 (98.0)
Iron deficiency anemia, n (%)
373 (81.3)
Iron deficiency without anemia, n (%)
77 (16.8)
Cumulative FCM treatment dose, n (%)
500 mg
122 (26.6)
501–1000 mg
290 (63.2)
1001–3000 mg
47 (10.2)
Diagnosis per ICD-10 high level category, n (%)
Diseases of the digestive system
199 (43.4)
Diseases of the genitourinary system
121 (26.4)
Neoplasms
47 (10.2)
Diseases of the circulatory system
38 (8.3)
Other diseases
54 (11.8)
FCM: ferric carboxymaltose; ICD-10: International Classification of Diseases 10th Revision.